Development of stabilised mixtures of fluorescent antibody in single-test packages for flow cytometry (Q12098)

From EU Knowledge Graph
Revision as of 20:50, 6 June 2020 by DG Regio (talk | contribs) (‎Changed an Item)
Jump to navigation Jump to search
Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
Development of stabilised mixtures of fluorescent antibody in single-test packages for flow cytometry
Project in Czech Republic financed by DG Regio

    Statements

    0 references
    11,165,000.0 Czech koruna
    0 references
    446,600.0 Euro
    10 January 2020
    0 references
    22,330,000.0 Czech koruna
    0 references
    893,200.0 Euro
    10 January 2020
    0 references
    50 percent
    0 references
    31 December 2020
    0 references
    EXBIO Praha, a.s.
    0 references
    0 references

    49°59'0.49"N, 14°30'9.11"E
    0 references
    25250
    0 references
    Cílem projektu je zvýšení kapacit vlastního VaV společnosti EXBIO Praha, a.s. v oblasti stabilizovaných směsí fluorescenčně značených protilátek v jednotestovém balení pro průtokovou cytometrii. Rozšíření VIK posílí postavení společnosti na světovém obchodu s monoklonálními protilátkami, jejich deriváty a diagnostickými soupravami pro klinickou diagnostiku ve zdravotnictví a umožní další rozšíření a diversifikaci produktů především do zdravotnické diagnostiky. a. (Czech)
    0 references
    The objective of the project is to increase the own R & D capacities of EXBIO Praha, a.s. in the area of stabilised mixtures of fluorescent antibody in single-test packages for flow cytometry. The extension of the VIK will strengthen the company’s position in world trade in monoclonal antibodies, their derivatives and diagnostic kits for clinical diagnosis in the health sector and allow for the further expansion and diversification of products mainly in health diagnostics. a. (English)
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/17_165/0015522
    0 references